Corticosteroid Plus Pentoxifylline Is Not Better than Corticosteroid Alone for Improving Survival in Severe Alcoholic Hepatitis (COPE Trial)
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Corticosteroids and pentoxifylline reduce short-term mortality in severe alcoholic hepatitis (SAH), but not to the extent desired. Combining both drugs may lead to better survival, but has not yet been studied.
To compare the efficacy of corticosteroids plus pentoxifylline with that of corticosteroids alone in improving survival of SAH patients.
Of the 111 patients screened, 70 patients with SAH (Maddrey discriminant function (MDF) ≥ 32) were enrolled. Patients with active infection, bleeding, renal failure, or pancreatitis were excluded. Treatment was given for four weeks to group A (n = 36; prednisolone 40 mg/day plus pentoxifylline 400 mg thrice/day) and group B (n = 34; prednisolone 40 mg/day). Patients were followed up for 6 months. Data are expressed as median (range) or percentage.
Baseline characteristics of the two groups were similar (MDF group A 78.5 (36.8–140.9), group B 74.9 (45.6–140.2)). Four-week and six-month survival in groups A and B were not significantly different (four-week 72.2 and 73.5%, respectively, p = 1.00; six-month 30.6 and 23.5%, respectively, p = 0.417). At seven days, 55.6% of patients in group A and 64.7% in group B had a Lille score <0.45 (p = 0.473). Six-month survival was significantly higher for patients with a Lille Score <0.45 than for those with a Lille score ≥0.45 (group A 55.5 vs. 0%, p = 0.0006; group B 36 vs. 0%, p = 0.0304). Biological improvement at 28 days was significant for both groups; however, the difference between the groups was not significant.
For patients with severe alcoholic hepatitis, a combination of corticosteroids and pentoxifylline has no additional survival advantage compared with corticosteroids alone.
- Mathurin P. Corticosteroids for alcoholic hepatitis—what’s next? J Hepatol. 2005;43:526–533. CrossRef
- Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009;360:2758–2769. CrossRef
- Taieb J, Mathurin P, Elbim C, et al. Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids. J Hepatol. 2000;32:579–586. CrossRef
- Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med. 1990;172:391–394. CrossRef
- Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis: a meta analysis adjusting for confounding variables. Ann Intern Med. 1990;113:299–307.
- Daures JP, Peray P, Bories P, et al. Corticoid therapy in the treatment of acute alcoholic hepatitis. Results of a meta-analysis. Gastroenterol Clin Biol. 1991;15:223–228.
- Mathurin P, Mendenhall CL, Carithers RL Jr, et al. Corticosteroids improve short term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol. 2002;36:480–487. CrossRef
- Mathurin P, O’Grady J, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut. 2011;60:255–260. CrossRef
- Christensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta analysis adjusting for confounding variables. Gut. 1995;37:113–118. CrossRef
- Rambaldi A, Saconato HH, Christensen E, et al. Systematic review: glucocorticosteroids for alcoholic hepatitis—a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther. 2008;27:1167–1178. CrossRef
- Imperiale TF, O’Connor J, McCullough AJ. Corticosteroids are effective in patients with severe alcoholic patients. Am J Gastroenterol. 1999;94:3066–3067. CrossRef
- Christensen E. Alcoholic hepatitis—glucocorticosteroids or not? J Hepatol. 2002;36:547–548. CrossRef
- Mathurin P. The use of corticosteroids in severe alcohol hepatitis: we need to look beyond this controversy. J Hepatol. 2010;53:392–393. CrossRef
- Christensen E. Glucocorticosteroids in acute alcoholic hepatitis: the evidence of a beneficial effect is getting even weaker. J Hepatol. 2010;53:390–391. CrossRef
- Mc Cullough AJ, O’ Connor JF. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol. 1998;93:2022–2036.
- O’Shea RS, McCullough AJ. Treatment of alcoholic hepatitis. Clin Liver Dis. 2005;9:103–134. CrossRef
- O’Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Am J Gastroenterol. 2010;105:14–32. CrossRef
- Sass DA, Shaikh OS. Alcoholic hepatitis. Clin Liver Dis. 2006;10:219–237. CrossRef
- Doherty GM, Jensen JC, Alexander HR, et al. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery. 1991;110:192–198.
- Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:1637–1648. CrossRef
- Sidhu SS, Goyal O, Singla M, et al. Pentoxifylline in severe alcoholic hepatitis: a prospective randomized trial. Trop Gastroenterol. 2009;30:S21–S22.
- De BK, Gangopadhyay S, Dutta D, et al. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol. 2009;15:1613–1619. CrossRef
- Louvet A, Diaz E, Dharancy S, et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol. 2008;48:465–470. CrossRef
- Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23:164–176. CrossRef
- Mathurin P, Moreno C, Samuel D, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011;365:1790–1800. CrossRef
- Louvet A, Naveau S, Abdelnour M, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007;45:1348–1354. CrossRef
- Mathurin P, Abdelnour M, Ramond MJ, et al. Early change in bilirubin levels (ECBL) is an important prognostic factor in severe biopsy proven alcoholic hepatitis (AH) treated by prednisolone. Hepatology. 2003;38:1363–1369.
- Mathurin P, Louvet A, Dao T, et al. Addition of pentoxifylline to prednisolone for severe alcoholic hepatitis does not improve 6-month survival: results of the Corpentox trial. Hepatology. 2011;54:81A.
- Mendenhall C, Roselle GA, Gartside P, et al. Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans administration cooperative studies. Alcohol Clin Exp Res. 1995;19:635–641. CrossRef
- Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005;41:353–358. CrossRef
- Dureja P, Lucey MR. The place of liver transplantation in the treatment of severe alcoholic hepatitis. J Hepatol. 2010;52:759–764. CrossRef
- Singal AK, Bashar H, Anand BS, et al. Graft and patient survival after liver transplantation for alcoholic hepatitis—comparison to alcoholic cirrhosis: exploratory analysis based on UNOS data. Hepatology. 2011;54:162A.
- Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011;365:1781–1789. CrossRef
- Brown RS Jr. Transplantation for alcoholic hepatitis—time to rethink the 6-month “rule.” N Engl J Med. 2011;365:1836–1838. CrossRef
- Corticosteroid Plus Pentoxifylline Is Not Better than Corticosteroid Alone for Improving Survival in Severe Alcoholic Hepatitis (COPE Trial)
Digestive Diseases and Sciences
Volume 57, Issue 6 , pp 1664-1671
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Lille score
- Severe alcoholic hepatitis
- Industry Sectors
- Author Affiliations
- 1. Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, 141001, Punjab, India
- 2. Department of Medicine, Dayanand Medical College and Hospital, Ludhiana, Punjab, India
- 3. Department of Community Medicine, Dayanand Medical College and Hospital, Ludhiana, Punjab, India